Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies
Study Details
Study Description
Brief Summary
This study is a multi-center, forward-looking, open, randomized, controlled clinical trial. This study aims to analyze the effects of Mecapegfilgrastim Injection prevention versus non-prevention for neutropenia in ovarian cancer, cervical cancer, endometrial cancer patients after chemical therapy.
Patients are randomized into study group and control group. All patients receive PTX+platinum chemotherapy of 3 weeks. In study group, patients accept PEG-rhG-CSF 24-48 hours from the chemotherapy. While the control group patients are only observed closely. Patient receive three courses of treatment.
The primary end is the incidence of 3/4 level neutropenia in three courses of chemotherapy.
The secondary ends include: the incidences and duration of neutropenia in every course of chemotherapy, the incidences of FN in three courses and every course of chemotherapy, the incidences of infection in three courses and every course of chemotherapy, the delay time of the next cycle of chemotherapy due to FN or infection, the RDI of the second and third cycles of chemotherapy, adverse events related to G-CSF, quality of life, cost of medicine and admitting.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: PEG-rhG-CSF prevention Mecapegfilgrastim subcutaneous injection, 6mg, 24-48h after the end of antitumor drug administration in each chemotherapy cycle, |
Other: Mecapegfilgrastim Injection
24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle
Other Names:
|
| No Intervention: non-prevention Only close monitoring after chemotherapy |
Outcome Measures
Primary Outcome Measures
- Incidence of third/fourth level neutropenia [three months]
Incidence of third/fourth level neutropenia during three cycles chemotherapy
Secondary Outcome Measures
- Incidence of febrile neutropenia [three months]
Incidence of febrile neutropenia during every cycle chemotherapy
- The duration time of third/fourth level neutropenia [three months]
The duration time of third/fourth level neutropenia during three cycles chemotherapy
- Incidence of infection [three months]
Incidence of third/fourth level neutropenia during three cycles chemotherapy
- delay time of chemotherapy [three months]
The delay time of the next cycle of chemotherapy due to FN or infection
- RDI of chemotherapy [three months]
Relative dose intensity of the second and third chemotherapy
- Adverse events [three months]
Incidence of adverse events related to granulocyte colony stimulating factor according to common Terminology Criteria for Adverse Events (CTCAE) v5.0
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ages 18-70
-
Weight ≥45 kg
-
≤2 lines chemotherapy or postoperative adjuvant chemotherapy patients with cervical cancer, ovarian cancer and endometrial cancer
-
Receive paclitaxel combined with platinum three weeks per cycle of chemotherapy
-
With an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1
-
Expected survival time of > 3 months
-
Main organ functions meet the following criteria:
-
Hb≥75g/L; WBC≥3.0×109/L; ANC≥1.5×109/L; PLT≥80×109/L;
-
APTT-ULN≤10s; PT-ULN≤3s; TT-ULN≤3s;
-
ALT≤2.5×ULN; AST≤2.5×ULN; TBIL≤2.5×ULN;
-
BUN≤1.5×ULN; Cr≤1.5×ULN; UA≤1.5×ULN；Creatinine clearance≥40mL/min;
-
without obvious cardiac dysfunction
- Provided consent for participation
Exclusion Criteria:
-
With uncontrollable infections or receive systemic antibiotics within 72 hours prior to chemotherapy
-
Pregnant or lactating women
-
Received bone marrow or hematopoietic stem cell transplantation within the past 3 months
-
Concurrent chemoradiotherapy
-
Presence of hematological disorders: systemic lupus erythematosus, sjogren's syndrome, rheumatic autoimmune disease, mixed and hoof tissue disease, autoimmune hemolytic anemia, leukopenia , chronic granulocyte leukemia, bone marrow dysplasia syndrome, aplastic anemia, congenital and idiopathic neutropenia, myelodysplastic syndrome, cyclic neutropenia, primary and secondary thrombocytopenic purpura, etc
-
Presence of risk of thrombus or high risk of clotting
-
Presence of psychosis, neurological disease or brain metastases from tumors
-
Presence of uncontrollable complicated disease including symptomatic congestive heart failure, uncontrollable hypertension, unstable angina pectoris, active peptic ulcer, or hemorrhagic disease
-
Presence of uncontrollable infectious diseases, active viral hepatitis, tuberculosis, HIV
-
Allergic to recombinant human granulocyte stimulating factor or other biological products of E. coli origin
-
Received clinical trials within 1 month prior to enrollment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | No. 270, Dongan Road, Xuhui District, Shanghai, China | Shanghai | Shanghai | China |
Sponsors and Collaborators
- Xiaohua Wu MD
Investigators
- Principal Investigator: Xiaohua Wu, MD&PHD, director of gynecologic oncology
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MA-GynC-II-001